摘要
为探讨抑癌基因P16蛋白在膀胱移行细胞癌中表达的临床意义，应用免疫组化法（ABC法）对69例膀胱移行细胞癌中抑癌基因P16蛋白产物进行检测。结果：69例膀胱癌标本中37例检测P16蛋白阳性（53．62％）。P16蛋白阳性率在Ⅰ、Ⅱ和Ⅲ级肿瘤中分别为69．57％（16／23）、56．25％（18／32）和21．43％（3／14）。在Tis～T1期和T2～T4期肿瘤中分别为70．59％（24／34）和37．14％（13／35）。P16蛋白表达阳性率随着膀优癌病理分级、临床分期的上升而逐渐下降。其阳性率在肿瘤的病理分级、临床分期和预后等方面均有显著性差异（P＜0．05）。认为P16蛋白在抑制膀胱肿瘤的发生、发展中起着重要作用，可作为膀胱癌的生物学瘤标。
Protein product of Pl6 was detected by immunohistochemical method in 69 specimens of transitional cell bladder carcinoma. P16 was positive in 37 of 69 (53. 62% ). The P16 positive rate in grade Ⅰ, Ⅱ andⅢ tumors was 69. 57% (16/23),56. 25% (18/32),21. 43% (3/14) respecively and in stage Tis^T1 and T2~T4 tumors being 70. 59% (24/34) and 37. 14% (13/35).The P16 positive rates were significantly lower in poorly differentiated and invasive bladder cancer.Expression of P16 correlated well with histological grade,clinical stage and prognosis. The results showed that there was a important role of the P16 tumor suppressor gene protein in the development and for the progression of bladder cancer. P16 could be used as a tumor marker for bladder cancer.
出处
《临床泌尿外科杂志》
1997年第1期36-38,53,共4页
Journal of Clinical Urology
